Volume 22 (2023)
Volume 21 (2022)
Volume 20 (2021)
Volume 19 (2020)
Volume 18 (2019)
Volume 17 (2018)
Volume 16 (2017)
Volume 15 (2016)
Volume 14 (2015)
Volume 13 (2014)
Volume 12 (2013)
Volume 11 (2012)
Volume 10 (2011)
The efficacy and safety of oral disease-modifying therapies for relapsing-remitting multiple sclerosis: A systematic review

Rahil Sadat Shahtaheri; Shekoufeh Nikfar; Elahe Khorasani; Mansoureh Sabbagh-Baniazad; Zahra Goudarzi; Maziar Emamikhah

Volume 19, Issue 3 , July 2020, , Pages 138-145


  Background: Although widely used, first-line injectable medicines for the treatment of multiple sclerosis (MS) remain an issue of efficacy and adherence. Recently, new oral medications for MS have contributed to dramatic improvements in MS treatment. This study aims to evaluate the safety and efficacy ...  Read More

Direct and indirect cost of managing Alzheimer’s disease in the Islamic Republic of Iran

Zahra Aajami; Abbas Kebriaeezadeh

Volume 18, Issue 1 , January 2019, , Pages 7-12

  Background: Alzheimer’s disease (AD) affects a large number of adults annually all around the world. The monetary cost of this disorder is huge. This study aims to estimate the cost of AD in Iran by considering stages of disease. Methods: A cross-sectional study was designed from July to December ...  Read More

Pegylated versus non-pegylated interferon beta 1a in patients with relapsing-remitting multiple sclerosis: A cost-effectiveness analysis

Amir Hashemi-Meshkini; Hedieh Sadat Zekri; Hasan Karimi-Yazdi; Pardis Zaboli; MohammadAli Sahraian; Shekoufeh Nikfar

Volume 17, Issue 3 , July 2018, , Pages 123-128

  Background: Pegylated (PEG) interferon beta 1a has been approved by the United States Food and Drug Administration (USFDA) as an alternative to interferon beta 1a for multiple sclerosis (MS). Due to its higher price, this study aimed to evaluate the cost-effectiveness of PEG-interferon beta 1-a compared ...  Read More